About Verona Pharma
Verona Pharma is a publicly listed company based in London (United Kingdom) founded in 2005, and was acquired by Merck in July 2025. Respiratory disease drugs for asthma and COPD are developed. Verona Pharma has raised $56.02 million across 4 funding rounds from investors including Merck, Orbimed and Janus Henderson Investors. The company has 209 employees. Verona Pharma offers products and services including Respiratory Therapeutics and Pipeline Programs. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its legal entity is VERONA PHARMA PLC.
Company details
Verona Pharma was founded in 2005 in London, United Kingdom, and operates in the pharmaceutical sector focused on respiratory conditions. A drug pipeline is maintained, including RPL-554 in Phase 2 trials for chronic obstructive pulmonary disease, cystic fibrosis, and asthma. VRP700 for cough management is available for out-licensing. Novel anti-inflammatory polysaccharides from marine organisms like starfish are also identified as sources without anticoagulant effects.
- Headquarters London, United Kingdom
- Employees 209
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website veronapharma.com
- Social LinkedIn X
- Acquired by Merck (Jul 2025)
- Legal Name Verona Pharma Plc Sponsored Adr
- Annual Revenue$42.3 M (USD)as on Dec 31, 2024
- Net Profit-$173.49 M (USD)-217.87as on Dec 31, 2024
- EBITDA-$153.63 M (USD)-128.79as on Dec 31, 2024
- Total Equity Funding$56.02M (USD)
in 4 rounds
- Latest Funding Round$200.16M (USD), Post-IPO
Jul 2020
- InvestorsMerck
& 16 more
- Employee Count209
- Acquired byMerck
(Jul 2025)
Products & Services of Verona Pharma
Verona Pharma offers a comprehensive portfolio of products and services, including Respiratory Therapeutics and Pipeline Programs.
Develops treatments for chronic respiratory diseases like COPD.
Builds portfolio of novel respiratory drugs for various conditions.
Funding Insights of Verona Pharma
Verona Pharma has successfully raised a total of $56.02M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200.16 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56.02M
- Total Rounds 4
- Last Round Post-IPO — $200.16M
- First Round $11.5M
(Feb 2012)
- Investors Count 16
All 4 funding rounds of Verona Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $200.16M | Post-IPO | – | – | |
| Jun 2016 | $44.52M | Series C | – | – | |
| Nov 2014 | Grant | – | – | ||
| Feb 2012 | $11.5M | Series A | – | – |
17 investors in total: 17 institutional.
Investors in Verona Pharma
Verona Pharma has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| acornbioventures.com | ||||
PE firm investing in the US | pbmcap.com | Charlottesville, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
| soleuscapital.com | ||||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for Verona Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Verona Pharma
84 people are tracked at Verona Pharma (47 in leadership, 8 in board & advisors, 29 in team); the tracked headcount is 209.
| Name | Role | Group |
|---|---|---|
Kathleen Rickard | Chief Medical Officer | Leadership |
Jim Willis | National Sales Director | Leadership |
Mark W. Hahn | Chief Financial Officer | Leadership |
Candice Clay, Ph.D. | Field Medical Director | Leadership |
Amelia Winter | Associate Director, Talent Acquisition | Leadership |
A. Burak Uçar, PhD | Sr. Director, Commercial Manufacturing & Technical Operations | Leadership |
W. Blake Burnette | Executive Director of Marketing | Leadership |
Umang Desai, PharmD | Field Medical Director - East | Leadership |
Tuan le | Regional Sales Director | Leadership |
Tim Craney | Regional Sales Director | Leadership |
Oliver Poulain | Senior Director, Finance | Leadership |
Amy Dixon, PharmD | Executive Director, Medical Affairs | Leadership |
Rachel Hunter, CPA | Vice President Finance | Leadership |
Kavita Aggarwal | Senior Vice President, Medical Affairs | Leadership |
Mark Zappia | Vice President of Commercial Operations | Leadership |
Jaime Hilliard | Sr. Director, Market Research & Forecasting | Leadership |
Matt Casbon | Vice President, Sales, Marketing & Training | Leadership |
Chris M. | Chief Commercial Officer (cco) | Leadership |
Minh Lu | VP, Commercial Supply Chain | Leadership |
Jeff Hill | Vice President, Digital and Information Technology | Leadership |
64 more people are available in the full profile.
Complete people profiles for Verona Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Verona Pharma
Verona Pharma is a publicly listed company on the NASDAQ with ticker symbol VRNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Apr 2017
- Listed onNASDAQ: VRNA
- Listed entityVerona Pharma plc Sponsored ADR
- Exchange sectorHealth technology
- Share price$106.69 · 2025-09-29
- Market capitalisation$9.17B
- EPS (diluted, trailing year)$-1.03
- Volume (last session)1,268,229
- Analyst consensusNeutral
Financials of Verona Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $42.3M | -$173.5M | -$153.6M |
| 2023 | -$54.6M | -$67.2M | |
| 2022 | $457,720 | -$68.7M | -$75.1M |
| 2021 | $40.0M | -$55.6M | -$72.7M |
| 2020 | -$65.7M | -$74.2M |
Detailed financial statements for Verona Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Verona Pharma
5 dated milestones of Verona Pharma across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Verona Pharma is founded.
- Funding First funding round of $11.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $200.2M.
- Exit Acquired by Merck.
Web traffic of Verona Pharma
The website of Verona Pharma (veronapharma.com) receives about 7.7K visits a month and ranks #2,500,388 among all websites worldwide, #3,433 in Biotechnology and Pharmaceuticals.
- Monthly visits7.7K
▼ 12.3% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,500,388
among all websites
- Category rank#3,433
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.7
- Average visit16 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Verona Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| savarapharma.com | 100% | 4K | #3,870,989 | View details | |
| pharmaphorum.com | 96% | 128.2K | #451,885 | View details | |
zambongroup.com | zambongroup.com | 95% | – | ||
| manufacturingchemist.com | 93% | #1,139,602 | View details | ||
| salix.com | 93% | 15.6K | #1,433,848 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Verona Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verona Pharma
Complete news archive for Verona Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verona Pharma
Verona Pharma was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Verona Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Verona Pharma is a funded company, having raised a total of $56.02M across 4 funding rounds to date. The company's 1st funding round was a Series A of $11.5M, raised on Feb 2012.
Verona Pharma has 209 employees.
Annual revenue of Verona Pharma is $42.3M as on Dec 31, 2024.
Verona Pharma was founded in 2005 in London, United Kingdom, and operates in the pharmaceutical sector focused on respiratory conditions. A drug pipeline is maintained, including RPL-554 in Phase 2 trials for chronic obstructive pulmonary disease, cystic fibrosis, and asthma. VRP700 for cough management is available for out-licensing. Novel anti-inflammatory polysaccharides from marine organisms like starfish are also identified as sources without anticoagulant effects.
Verona Pharma offers Respiratory Therapeutics and Pipeline Programs.
Yes, Verona Pharma is publicly traded on NASDAQ under the ticker symbol VRNA.
Verona Pharma has 17 investors. Key investors include Merck, Orbimed, Janus Henderson Investors, RA Capital, and Perceptive Advisors.
Verona Pharma operates through Verona Pharma Plc.
Yes. Verona Pharma was acquired by Merck in July 2025.